slides · global inventory
Turn
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 37,461
Current window 25,411-25,440
Pages 1,249
Rows per page 30
Beat
25,411-25,440 of 37,461
06
The slide uses a before-after framing to justify the technical and economic superiority of a single-stack architecture.Hyzon | Results Presentation Deck | 15 slides · Hyzon
Conference presentation Investor relations Beat · Solution1 hit
13
The chart uses a trend arrow to emphasize the CAGR.IBEX | Investor Presentation Deck | 18 slides · ibex
Pitch deck Investor relations Beat · The Breakthrough1 hit
14
The bar chart shows a clear trend of decreasing US revenue and increasing Offshore/Nearshore revenue over 2021-2023.IBEX | Investor Presentation Deck | 18 slides · ibex
Pitch deck Investor relations Beat · The Breakthrough1 hit
15
The slide uses donut charts to illustrate client concentration metrics for Q1 FY24.IBEX | Investor Presentation Deck | 18 slides · ibex
Pitch deck Investor relations Beat · The Breakthrough1 hit
07
The slide uses a process flow structure to show how different AI applications contribute to productivity, quality, and volume boosts.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
08
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
09
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
Includes footnote regarding adjustment for legacy client exit.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
11
The slide uses a bar chart to show year-over-year growth in Adjusted EBITDA and lists key operational drivers.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
12
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
13
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
14
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
05
The slide uses a split-screen visual comparison to contrast traditional antibody approaches with the company's TCR-based platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a process-flow diagram to contrast personalized autologous therapy with off-the-shelf bispecific therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a Gantt-style visualization to show the progress of various drug candidates across different clinical phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
08
The slide outlines a partnership structure involving three distinct therapeutic approaches and a financial deal structure.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a timeline framework to demonstrate historical traction and partnership growth.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a list-based comparison to show market potential for specific drug targets.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
11
The slide uses a table to show market opportunity (prevalence) and a diagram to illustrate the mechanism of action for two different drug platforms.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
12
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a combination of a biological mechanism diagram, a checklist of target criteria, and histological images to validate the therapeutic target.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a circular process diagram to illustrate the therapy lifecycle, followed by a zoomed-in molecular interaction diagram.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
05
The slide uses a cause-and-effect structure to map platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
06
Uses a human anatomy diagram to map therapeutic areas to diseases; includes a pyramid at the bottom highlighting 'Other diseases' and the key differentiator 'Overcoming neurotoxicity'.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
07
Includes a cartoon illustration of a cell/virus character.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a structural diagram to highlight the specific modifications (COBRA Binder) that differentiate NXC-201 from the reference therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
05
Clinical trial results presentation.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit